News stories about Xencor (NASDAQ:XNCR) have trended somewhat positive on Sunday, according to Accern Sentiment. Accern identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Xencor earned a coverage optimism score of 0.09 on Accern’s scale. Accern also gave press coverage about the biopharmaceutical company an impact score of 47.7570746874925 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the news headlines that may have impacted Accern’s rankings:
- Brokerages Anticipate Xencor Inc (XNCR) to Announce -$0.27 EPS (americanbankingnews.com)
- Xencor Inc (XNCR) Insider Sells $260,300.00 in Stock (americanbankingnews.com)
- Cantor Fitzgerald Initiates Coverage on Xencor (XNCR) (americanbankingnews.com)
- Xencor Doses First Patient in Phase 1 Study of XmAb®18087 Bispecific Tumor Targeting Antibody for the Treatment of Neuroendocrine Tumors and Gastrointestinal Stromal Tumors (finance.yahoo.com)
- Xencor (XNCR) Stock Rating Upgraded by Zacks Investment Research (americanbankingnews.com)
Several equities research analysts have commented on XNCR shares. Piper Jaffray Companies restated a “buy” rating and issued a $35.00 target price on shares of Xencor in a research note on Sunday, November 12th. Cantor Fitzgerald started coverage on Xencor in a research note on Thursday. They issued a “buy” rating and a $33.00 target price on the stock. Zacks Investment Research upgraded Xencor from a “sell” rating to a “hold” rating in a research note on Tuesday, February 20th. Finally, BidaskClub upgraded Xencor from a “sell” rating to a “hold” rating in a research note on Thursday, February 15th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus target price of $30.80.
Shares of Xencor (XNCR) opened at $27.64 on Friday. The company has a market capitalization of $1,360.00, a P/E ratio of -27.37 and a beta of 1.97. Xencor has a 12 month low of $18.55 and a 12 month high of $28.64.
In related news, major shareholder John S. Stafford III acquired 15,374 shares of the company’s stock in a transaction dated Tuesday, November 28th. The shares were bought at an average price of $19.86 per share, for a total transaction of $305,327.64. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Paul A. Foster sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, February 22nd. The stock was sold at an average price of $26.03, for a total value of $260,300.00. Following the sale, the insider now owns 12,419 shares in the company, valued at approximately $323,266.57. The disclosure for this sale can be found here. Insiders acquired a total of 30,804 shares of company stock worth $625,406 in the last 90 days. Company insiders own 4.03% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This piece of content was originally published by Transcript Daily and is the sole property of of Transcript Daily. If you are reading this piece of content on another website, it was stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece of content can be accessed at https://transcriptdaily.com/2018/02/25/xencor-xncr-earns-media-impact-score-of-0-09.html.
Xencor Company Profile
Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.